<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01696539</url>
  </required_header>
  <id_info>
    <org_study_id>Spartacus01</org_study_id>
    <nct_id>NCT01696539</nct_id>
  </id_info>
  <brief_title>Steps for PRosTAte Cancer Health and Survival (SPaRTACuS): Pilot Study of a Walking Intervention to Improve Health and Quality of Life in Prostate Cancer Patients</brief_title>
  <official_title>Pilot Intervention Study of the Impact of Sustainable Daily Physical Activity on Health and Quality of Life in a Cohort of Men With Prostate Cancer in Sweden: Steps for PRosTAte Cancer Health and Survival (SPaRTACuS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard School of Public Health (HSPH)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sustainable daily physical activity is&#xD;
      effective in improving biological indicators of health and self-reported quality of life in&#xD;
      men with prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Living with prostate cancer is a unique challenge faced by millions of men across the globe.&#xD;
      Existing research has indicated many potential methods of attenuating prostate cancer&#xD;
      progression and preserving patients' quality of life, but is lacking in definitive&#xD;
      conclusions regarding the effectiveness of these methods in practice. This study seeks to&#xD;
      further investigate the impact of post-diagnosis physical activity on biological indicators&#xD;
      of health and self-reported quality of life in a cohort of men with prostate cancer in&#xD;
      Sweden. Participants are randomized to either a walking intervention group, which encourages&#xD;
      walking 10,000 steps per day for one year, or to a standard-or-care control group, and&#xD;
      followed for 11 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <secondary_outcome>
    <measure>C-Reactive Protein</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-Density Lipoprotein</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Stress</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Self-reported stress level measured using the Perceived Stress Scale-4. Questionnaire completed by participant at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Sleep Quality</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Self-reported sleep quality measured using the Karolinska Sleepiness Scale. Questionnaire completed by participant at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Emotional Quality of Life</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Self-reported emotional quality of life using the 21-Item Depression Anxiety Stress Scale, DASS-21. Questionnaire completed by participant at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Reported Physical Quality of Life</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Self-reported physical quality of life measures related to urinary, bowel, and sexual function using the FACT-P questionnaire. Questionnaire completed by participant at start and 11 weeks after start of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blodpressur, systolic and diastolic.</measure>
    <time_frame>At time of randomisation(March 1, 2010) and after 11 weeks</time_frame>
    <description>Blodpressur systolic and diastolic, will be assesed by the clinican at randomisation and after 11 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Walking Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Walking Intervention</intervention_name>
    <description>Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.</description>
    <arm_group_label>Walking Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 80 years or younger&#xD;
&#xD;
          -  Histologic confirmation of prostate cancer&#xD;
&#xD;
          -  Clinically or pathologically staged as locally advanced or early metastatic prostate&#xD;
             cancer&#xD;
&#xD;
          -  Diagnosis within 1 year of study enrollment&#xD;
&#xD;
          -  Willing and able to walk 10,000 steps per day&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age greater than 80 years old at enrollment&#xD;
&#xD;
          -  Inability to understand the language spoken in host country&#xD;
&#xD;
          -  Physically unable to walk 100 meters unassisted&#xD;
&#xD;
          -  Diagnosed with dementia or severe psychiatric disease&#xD;
&#xD;
          -  Any prior cancer diagnosis&#xD;
&#xD;
          -  Has experienced a myocardial infarction or stroke within six months of cancer&#xD;
             diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ove Andren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OREBRO UNIVERSITY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orebro University</name>
      <address>
        <city>Orebro</city>
        <state>Narke</state>
        <zip>701-82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.oru.se/English/</url>
    <description>Orebro University English Homepage</description>
  </link>
  <link>
    <url>http://www.hsph.harvard.edu/</url>
    <description>Harvard School of Public Health Homepage</description>
  </link>
  <reference>
    <citation>Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011 Feb 20;29(6):726-32. doi: 10.1200/JCO.2010.31.5226. Epub 2011 Jan 4.</citation>
    <PMID>21205749</PMID>
  </reference>
  <reference>
    <citation>Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C, Sweeney CJ. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol. 2011 Apr;22(4):801-807. doi: 10.1093/annonc/mdq443. Epub 2010 Sep 29.</citation>
    <PMID>20880998</PMID>
  </reference>
  <reference>
    <citation>Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther. 2008 Jan;7(1):59-70. doi: 10.1158/1535-7163.MCT-07-0329.</citation>
    <PMID>18202010</PMID>
  </reference>
  <reference>
    <citation>Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003 Aug 20;95(16):1240-4. doi: 10.1093/jnci/djg009.</citation>
    <PMID>12928350</PMID>
  </reference>
  <reference>
    <citation>Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25. doi: 10.1093/jnci/djj499.</citation>
    <PMID>17179483</PMID>
  </reference>
  <reference>
    <citation>Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, Ma J. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010 Jan;56(1):34-43. doi: 10.1373/clinchem.2009.133272. Epub 2009 Nov 12.</citation>
    <PMID>19910504</PMID>
  </reference>
  <reference>
    <citation>Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol. 2011 Jan 1;29(1):47-53. doi: 10.1200/JCO.2010.28.4752. Epub 2010 Nov 29.</citation>
    <PMID>21115859</PMID>
  </reference>
  <reference>
    <citation>Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage. 2012 Jan;43(1):96-110. doi: 10.1016/j.jpainsymman.2011.03.006. Epub 2011 Jun 2.</citation>
    <PMID>21640547</PMID>
  </reference>
  <reference>
    <citation>Tudor-Locke C, Craig CL, Brown WJ, Clemes SA, De Cocker K, Giles-Corti B, Hatano Y, Inoue S, Matsudo SM, Mutrie N, Oppert JM, Rowe DA, Schmidt MD, Schofield GM, Spence JC, Teixeira PJ, Tully MA, Blair SN. How many steps/day are enough? For adults. Int J Behav Nutr Phys Act. 2011 Jul 28;8:79. doi: 10.1186/1479-5868-8-79.</citation>
    <PMID>21798015</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 16, 2012</study_first_submitted>
  <study_first_submitted_qc>September 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2012</study_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Örebro University, Sweden</investigator_affiliation>
    <investigator_full_name>Ove Andrén</investigator_full_name>
    <investigator_title>Associate Professor and Chair of Urology</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01696539
org study id: Spartacus01
nct id: NCT01696539
lead sponsor: 
collaborator: 
has dmc: Yes
The purpose of this study is to determine whether sustainable daily physical activity is
      effective in improving biological indicators of health and self-reported quality of life in
      men with prostate cancer.
Living with prostate cancer is a unique challenge faced by millions of men across the globe.
      Existing research has indicated many potential methods of attenuating prostate cancer
      progression and preserving patients' quality of life, but is lacking in definitive
      conclusions regarding the effectiveness of these methods in practice. This study seeks to
      further investigate the impact of post-diagnosis physical activity on biological indicators
      of health and self-reported quality of life in a cohort of men with prostate cancer in
      Sweden. Participants are randomized to either a walking intervention group, which encourages
      walking 10,000 steps per day for one year, or to a standard-or-care control group, and
      followed for 11 weeks.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Supportive Care
masking: Single (Outcomes Assessor)
measure: C-Reactive Protein
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.
measure: High-Density Lipoprotein
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.
measure: Adiponectin
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.
measure: Total Cholesterol
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.
measure: Triglycerides
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.
measure: Insulin
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.
measure: Testosterone
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.
measure: Estradiol
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Levels assessed in blood. Blood draw performed by clinician at start and 11 weeks after start of intervention.
measure: Self-Reported Stress
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Self-reported stress level measured using the Perceived Stress Scale-4. Questionnaire completed by participant at start and 11 weeks after start of intervention.
measure: Self-Reported Sleep Quality
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Self-reported sleep quality measured using the Karolinska Sleepiness Scale. Questionnaire completed by participant at start and 11 weeks after start of intervention.
measure: Self-Reported Emotional Quality of Life
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Self-reported emotional quality of life using the 21-Item Depression Anxiety Stress Scale, DASS-21. Questionnaire completed by participant at start and 11 weeks after start of intervention.
measure: Self-Reported Physical Quality of Life
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Self-reported physical quality of life measures related to urinary, bowel, and sexual function using the FACT-P questionnaire. Questionnaire completed by participant at start and 11 weeks after start of intervention.
measure: Blodpressur, systolic and diastolic.
time frame: At time of randomisation(March 1, 2010) and after 11 weeks
description: Blodpressur systolic and diastolic, will be assesed by the clinican at randomisation and after 11 weeks
arm group label: Walking Intervention
arm group type: Experimental
description: Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
arm group label: Standard of Care
arm group type: Active Comparator
description: Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
intervention type: Behavioral
intervention name: Walking Intervention
description: Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
arm group label: Walking Intervention
intervention type: Other
intervention name: Standard of Care
description: Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
arm group label: Standard of Care
criteria: 
gender: Male
minimum age: 40 Years
maximum age: 80 Years
healthy volunteers: No
last name: Ove Andren, PhD
role: Principal Investigator
affiliation: OREBRO UNIVERSITY
facility: 
country: Sweden
url: http://www.oru.se/English/
description: Orebro University English Homepage
url: http://www.hsph.harvard.edu/
description: Harvard School of Public Health Homepage
citation: Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011 Feb 20;29(6):726-32. doi: 10.1200/JCO.2010.31.5226. Epub 2011 Jan 4.
PMID: 21205749
citation: Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C, Sweeney CJ. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol. 2011 Apr;22(4):801-807. doi: 10.1093/annonc/mdq443. Epub 2010 Sep 29.
PMID: 20880998
citation: Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther. 2008 Jan;7(1):59-70. doi: 10.1158/1535-7163.MCT-07-0329.
PMID: 18202010
citation: Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003 Aug 20;95(16):1240-4. doi: 10.1093/jnci/djg009.
PMID: 12928350
citation: Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25. doi: 10.1093/jnci/djj499.
PMID: 17179483
citation: Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, Ma J. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem. 2010 Jan;56(1):34-43. doi: 10.1373/clinchem.2009.133272. Epub 2009 Nov 12.
PMID: 19910504
citation: Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol. 2011 Jan 1;29(1):47-53. doi: 10.1200/JCO.2010.28.4752. Epub 2010 Nov 29.
PMID: 21115859
citation: Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom Manage. 2012 Jan;43(1):96-110. doi: 10.1016/j.jpainsymman.2011.03.006. Epub 2011 Jun 2.
PMID: 21640547
citation: Tudor-Locke C, Craig CL, Brown WJ, Clemes SA, De Cocker K, Giles-Corti B, Hatano Y, Inoue S, Matsudo SM, Mutrie N, Oppert JM, Rowe DA, Schmidt MD, Schofield GM, Spence JC, Teixeira PJ, Tully MA, Blair SN. How many steps/day are enough? For adults. Int J Behav Nutr Phys Act. 2011 Jul 28;8:79. doi: 10.1186/1479-5868-8-79.
PMID: 21798015
responsible party type: Principal Investigator
investigator affiliation: Örebro University, Sweden
investigator full name: Ove Andrén
investigator title: Associate Professor and Chair of Urology
mesh term: Prostatic Neoplasms